The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer

by Aniello Cerrato, Roberta Visconti, Angela Celetti
Published 2018-02-01

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

by Aniello Cerrato, Francesco Morra, Angela Celetti
Published 2016-11-01

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors

by Daniela Criscuolo, Francesco Morra, Riccardo Giannella, Aniello Cerrato, Angela Celetti
Published 2019-06-01

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

by Daniela Criscuolo, Francesco Morra, Riccardo Giannella, Roberta Visconti, Aniello Cerrato, Angela Celetti
Published 2019-02-01

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

by Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano, Angela Celetti
Published 2019-02-01

Wnt/Tcf1 pathway restricts embryonic stem cell cycle through activation of the Ink4/Arf locus.

by Anchel De Jaime-Soguero, Francesco Aulicino, Gokhan Ertaylan, Anna Griego, Aniello Cerrato, Aravind Tallam, Antonio Del Sol, Maria Pia Cosma, Frederic Lluis
Published 2017-03-01